Baduanjin Exercising Effects on Sub-clinical Hypothyroidism and Cognitive Problems

Cognitive Impairment Clinical Trial

Official title:

Baduanjin Exercising Effects on Women With Hypothyroidism and Cognitive Problems

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05803967
• Other study ID #: P.T.REC/012/004294
• Status: Recruiting
• Phase: N/A
• Start date: December 18, 2022
• Est. completion date: June 30, 2023

Study information

• Verified date: March 2023
• Source: Cairo University
• Contact: Ali MA Ismail
• Phone: 01005154209
• Email: ali.mohamed[@]pt.cu.edu.eg
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Females with sub-clinical hypothyroidism may exhibit frequent cognitive problems especially if they are elderly

Description:

Females (forty in number) with sub-clinical hypothyroidism exhibit cognitive problems, they are elderly, will be divided to exercised group (baduanjin training will be applied 5 times per the week, under supervision for 12 weeks, number of patients will be 20) and other non exercised group (number of patients will be 20) . all women of groups will received their prescribed daily one-dose medication tablet (levothyroxine).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: June 30, 2023
• Est. primary completion date: June 18, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 65 Years to 75 Years

Eligibility

Inclusion Criteria:

• female with sub-clinical hypothyroidism

• females with mild cognitive impairment

• females with obesity (obesity class one)

Exclusion Criteria:

• neurological problems

• orthopedic problems

Related Conditions & MeSH terms

• Cognitive Impairment
• Hypothyroidism
• Subclinical hypothyroïdism

Intervention

Behavioral:
• Baduanjin exercising
baduanjin will be applied 5 times per the week, under supervision, for 12 weeks,

Locations

Country	Name	City	State
Egypt	Cairo Unoversity	Giza

Sponsors (1)

Lead Sponsor	Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	thyroid stimulating hormone	will be measured in serum of women with hypothyroidism	it will be measured after 12 weeks
Secondary	systolic blood pressure	will be measured by manual sphygmomanometer	it will be measured after 12 weeks
Secondary	triglycerides	will be measured in serum of women with hypothyroidism	it will be measured after 12 weeks
Secondary	Addenbrooke Cognitive Examination	will assess Cognitive impairment	it will be measured after 12 weeks
Secondary	diastolic blood pressure	will be measured by manual sphygmomanometer	it will be measured after 12 weeks
Secondary	low density lipoprotein	will be measured in serum of women with hypothyroidism	it will be measured after 12 weeks
Secondary	cholesterol	will be measured in serum of women with hypothyroidism	it will be measured after 12 weeks
Secondary	high density lipoprotein	will be measured in serum of women with hypothyroidism	it will be measured after 12 weeks
Secondary	body mass index	it will be measure on empty bladder and stomach	it will be measured after 12 weeks